​

Exelixis, Inc.

NasdaqGS:EXEL Stock Report

Market Cap: US$12.2b

Exelixis (EXEL) Stock Overview

An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. More details

EXEL fundamental analysis
Snowflake Score
Valuation4/6
Future Growth5/6
Past Performance6/6
Financial Health6/6
Dividends0/6

Rewards

Trading at 84.5% below our estimate of its fair value

Earnings are forecast to grow 20.53% per year

Earnings grew by 213.9% over the past year

Risk Analysis

Significant insider selling over the past 3 months


EXEL Community Fair Values

Create Narrative

See what 112 others think this stock is worth. Follow their fair value or set your own to get alerts.

EXEL logo
Exelixis
AN
AnalystConsensusTarget
Consensus Narrative from 19 Analysts

Zanzalintinib Pivotal Trials Will Unveil New Cancer Treatment Options

Key Takeaways Anticipated cabozantinib approval for NET indications is expected to expand CABOMETYX's market significantly, driving revenue growth. Business development focusing on late-stage GU/GI assets could enhance portfolio and drive growth through strategic acquisitions or partnerships.
View narrative
US$40.69
FV
10.2% overvalued intrinsic discount
9.68%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
40users have followed this narrative
2 months ago author updated this narrative
EXEL logo
Exelixis
AN
AnalystHighTarget
Consensus Narrative from 19 Analysts

CABOMETYX Trials And Biomarker Therapies Will Expand Global Oncology

Key Takeaways Expansion into new oncology markets and strong performance of lead therapies position the company for sustained revenue and operating leverage in a growing sector. Ongoing pipeline development and R&D innovation support diversification, enhanced value, and future earnings growth amid industry consolidation.
View narrative
US$60.00
FV
25.2% undervalued intrinsic discount
19.56%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
about 8 hours ago author updated this narrative
EXEL logo
Exelixis
AN
AnalystLowTarget
Consensus Narrative from 19 Analysts

Patent Expirations And Pricing Pressures Will Constrain Viability

Key Takeaways Heavy reliance on a single product exposes Exelixis to risks from patent loss, generics, pricing pressures, and regulatory changes, threatening long-term revenue and profitability. Challenges in diversifying the pipeline and a shift toward advanced oncology therapies could erode market share, with innovation efforts unlikely to offset structural industry changes.
View narrative
US$36.00
FV
24.6% overvalued intrinsic discount
3.75%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
about 9 hours ago author updated this narrative
View Exelixis Community

Exelixis, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Exelixis
Historical stock prices
Current Share PriceUS$44.86
52 Week HighUS$49.62
52 Week LowUS$22.20
Beta0.28
1 Month Change7.86%
3 Month Change22.77%
1 Year Change98.94%
3 Year Change107.97%
5 Year Change75.23%
Change since IPO195.37%

Recent News & Updates

Exelixis: I Was Wrong To Be Too Cautious (Rating Upgrade)

Jul 08

Recent updates

Exelixis: I Was Wrong To Be Too Cautious (Rating Upgrade)

Jul 08

With EPS Growth And More, Exelixis (NASDAQ:EXEL) Makes An Interesting Case

May 09
With EPS Growth And More, Exelixis (NASDAQ:EXEL) Makes An Interesting Case

Market Participants Recognise Exelixis, Inc.'s (NASDAQ:EXEL) Earnings

Apr 16
Market Participants Recognise Exelixis, Inc.'s (NASDAQ:EXEL) Earnings

Exelixis: Pinning Hopes On Cracking One Of The Toughest Nuts

Mar 13

Exelixis' (NASDAQ:EXEL) Earnings May Just Be The Starting Point

Feb 21
Exelixis' (NASDAQ:EXEL) Earnings May Just Be The Starting Point

Exelixis: Bullish On Cabo, Not So Convinced By It's Long-Term Replacement, Zanza

Jan 09

Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine

Oct 31

Exelixis, Inc.'s (NASDAQ:EXEL) Shares Leap 25% Yet They're Still Not Telling The Full Story

Oct 31
Exelixis, Inc.'s (NASDAQ:EXEL) Shares Leap 25% Yet They're Still Not Telling The Full Story

Here's Why We Think Exelixis (NASDAQ:EXEL) Is Well Worth Watching

Oct 26
Here's Why We Think Exelixis (NASDAQ:EXEL) Is Well Worth Watching

Getting In Cheap On Exelixis, Inc. (NASDAQ:EXEL) Might Be Difficult

Sep 02
Getting In Cheap On Exelixis, Inc. (NASDAQ:EXEL) Might Be Difficult
author-image

Cabozantinib's Momentum And Tactical Growth Amid Market Challenges Propel Biotech Innovation

Strong commercial performance of the cabozantinib franchise, indicating sustained revenue growth through market penetration and diversification into new indications.

Exelixis Comes Up Aces

Aug 08

Exelixis: With Patent Litigation Decision Due Soon, There Are Options

May 02

Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024

Mar 28

Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles

Jan 17

Shareholder Returns

EXELUS BiotechsUS Market
7D1.6%2.5%0.1%
1Y98.9%-11.7%11.4%

Return vs Industry: EXEL exceeded the US Biotechs industry which returned -11.7% over the past year.

Return vs Market: EXEL exceeded the US Market which returned 11.4% over the past year.

Price Volatility

Is EXEL's price volatile compared to industry and market?
EXEL volatility
EXEL Average Weekly Movement7.9%
Biotechs Industry Average Movement11.4%
Market Average Movement6.4%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.2%

Stable Share Price: EXEL has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: EXEL's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19941,147Mike Morrisseywww.exelixis.com

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors.

Exelixis, Inc. Fundamentals Summary

How do Exelixis's earnings and revenue compare to its market cap?
EXEL fundamental statistics
Market capUS$12.23b
Earnings (TTM)US$643.57m
Revenue (TTM)US$2.30b
19.0x
P/E Ratio
5.3x
P/S Ratio

Is EXEL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EXEL income statement (TTM)
RevenueUS$2.30b
Cost of RevenueUS$74.13m
Gross ProfitUS$2.22b
Other ExpensesUS$1.58b
EarningsUS$643.57m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)2.36
Gross Margin96.78%
Net Profit Margin27.99%
Debt/Equity Ratio0%

How did EXEL perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/14 14:22
End of Day Share Price 2025/07/11 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Exelixis, Inc. is covered by 42 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Peter LawsonBarclays
Jason Matthew GerberryBofA Global Research